Ferric Carboxymaltose in Patients with Acute Decompensated Heart Failure and Iron Deficiency: A Real-Life Study

Ferric Carboxymaltose in Patients with Acute Decompensated Heart Failure and Iron Deficiency: A Real-Life Study

<b>Background</b>: The correction of iron deficiency (ID) with ferric carboxymaltose (FCM) is a recommended intervention in heart failure (HF) with reduced ejection fraction. Our aim is to evaluate, in a real-life setting, the clinical significance of ID screening and FCM treatment in ac...

Full description

Bibliographic Details
Main Authors:	Federico Capone, Alberto Cipriani, Leonardo Molinari, Marianna Noale, Beatrice Gusella, Fabrizio Lucente, Sandro Savino, Antonella Bertomoro, Alois Saller, Sandro Giannini, Roberto Vettor
Format:	Article
Language:	English
Published:	MDPI AG 2023-08-01
Series:	Journal of Personalized Medicine
Subjects:	acute decompensated heart failure iron deficiency ferric carboxymaltose real-life experience
Online Access:	https://www.mdpi.com/2075-4426/13/8/1250

Similar Items

Does Repeated Dosing of Intravenous Ferric Carboxymaltose Alleviate Symptoms of Restless Legs Syndrome?
by: Hea Ree Park, et al.
Published: (2022-03-01)

Incidence of Hypophosphatemia after Ferric Carboxymaltose Treatment: Single Center Experience
by: Esra TERZİ DEMİRSOY
Published: (2021-08-01)

Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up
by: Antonio Lacquaniti, et al.
Published: (2020-09-01)

Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose—the randomized controlled HOMe aFers study
by: I. E. Emrich, et al.
Published: (2020-07-01)

Hypophoshatemia Incidence in Patients with Chronic Kidney Disease Treated with Intravenous Ferric Carboxymaltose and Factors Related to Hypophosphatemia
by: Abdullah Şumnu, et al.
Published: (2020-09-01)

Iron deficiency anemia with menorrhagia: Ferric carboxymaltose a safer alternative to blood transfusion
by: Vineet Mishra, et al.
Published: (2018-01-01)

Randomized controlled trial to compare injection ferric carboxymaltose and oral iron in reducing postpartum anemia: A multicenter, pilot study
by: Sushil Chawla, et al.
Published: (2022-01-01)

Fatal anaphylactic reaction due to ferric carboxymaltose: A case report
by: Aylin Mualla Arici, et al.
Published: (2020-07-01)

Seven-Year Single-Center Experience of the Efficacy and Safety of Ferric Carboxymaltose in Cancer Patients with Iron-Deficiency Anemia
by: Burak Yasin Aktaş, et al.
Published: (2023-11-01)

Switching iron sucrose to ferric carboxymaltose associates to better control of iron status in hemodialysis patients
by: Jesse M. G. Hofman, et al.
Published: (2018-09-01)

Symptomatic severe hypophosphatemia after intravenous ferric carboxymaltose
by: Wendy Fang, et al.
Published: (2019-10-01)

The Switch from Ferric Gluconate to Ferric Carboxymaltose in Hemodialysis Patients Acts on Iron Metabolism, Erythropoietin, and Costs: A Retrospective Analysis
by: Antonio Lacquaniti, et al.
Published: (2023-06-01)

Effectiveness of intravenous ferric carboxymaltose in improving hemoglobin level among postpartum women with moderate-to-severe anemia at a secondary care hospital in Faridabad, Haryana – An interventional study
by: Shashi Kant, et al.
Published: (2020-01-01)

Efficacy and safety of intravenous ferric carboxymaltose in iron deficiency anemia; Real-life data from Turkey, a single center experience
by: Ali Eser, et al.
Published: (2021-06-01)

A Pooled Analysis of Serum Phosphate Measurements and Potential Hypophosphataemia Events in 45 Interventional Trials with Ferric Carboxymaltose
by: Giuseppe Rosano, et al.
Published: (2020-11-01)

Hypophosphataemia risk associated with ferric carboxymaltose in heart failure: A pooled analysis of clinical trials
by: Giuseppe MC Rosano, et al.
Published: (2023-04-01)

Ferric carboxymaltose in patients with pulmonary arterial hypertension and iron deficiency: a long‐term study
by: Tilmann Kramer, et al.
Published: (2021-12-01)

Safety and effectiveness of ferric carboxymaltose intravenous therapy in pediatric patients with chronic kidney disease
by: Patricia Garcia-Ortega, et al.
Published: (2022-10-01)

Hypophosphataemia after ferric carboxymaltose is unrelated to symptoms, intestinal inflammation or vitamin D status
by: Wendy Fang, et al.
Published: (2020-06-01)

Ferric Carboxymaltose and Erythropoiesis-Stimulating Agent Treatment Reduces the Rate of Blood Transfusion in Refractory Anemia
by: Antonio Gidaro, et al.
Published: (2022-08-01)

Evaluation of iron stores in hemodialysis patients on maintenance ferric Carboxymaltose dosing
by: Matthias Diebold, et al.
Published: (2019-03-01)

Short‐term changes in left and right systolic function following ferric carboxymaltose: a substudy of the Myocardial‐IRON trial
by: Enrique Santas, et al.
Published: (2020-12-01)

Treatment of iron deficiency in patients after acute decompensation: a new target in the treatment of heart failure
by: I. V. Zhirov, et al.
Published: (2022-06-01)

Efficacy and Safety of Ferric Carboxymaltose in the Management of Iron Deficiency Anemia: A Multi-Center Real-World Study from India
by: Charmila A, et al.
Published: (2022-06-01)

Efficacy and safety of ferric carboxymaltose versus ferrous sulfate for iron deficiency anemia during pregnancy: subgroup analysis of Korean women
by: Jae-Yoon Shim, et al.
Published: (2018-08-01)

A comparative study of ferric carboxymaltose and iron sucrose as a parenteral iron treatment in iron deficiency anemia during pregnancy in a tertiary care hospital
by: Sandip Kumar Ghosh, et al.
Published: (2024-04-01)

Cost-minimization analysis in iron-deficiency anemia comparing intravenous ferric carboxymaltose to standard of care in pregnant women in Algeria
by: Lama Aladham, et al.
Published: (2023-01-01)

Differential Pharmacokinetics of Liver Tropism for Iron Sucrose, Ferric Carboxymaltose, and Iron Isomaltoside: A Clue to Their Safety for Dialysis Patients
by: Guy Rostoker, et al.
Published: (2022-07-01)

Effectiveness and safety of ferric carboxymaltose compared to iron sucrose in women with iron deficiency anemia: phase IV clinical trials
by: Amreen Naqash, et al.
Published: (2018-01-01)

Ferric Carboxymaltose Improves the Quality of Life of Patients with Inflammatory Bowel Disease and Iron Deficiency without Anaemia
by: Jose María Huguet, et al.
Published: (2022-05-01)

Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction
by: Raquel López‐Vilella, et al.
Published: (2022-02-01)

Efficacy and Safety of Intravenous Ferric Carboxymaltose in Patients with Postoperative Anemia Following Same-Day Bilateral Total Knee Arthroplasty: A Randomized Controlled Trial
by: Man Soo Kim, et al.
Published: (2021-04-01)

Cardiovascular, liver, and renal toxicity associated with an intravenous ferric carboxymaltose similar versus the originator compound
by: Toblli JE, et al.
Published: (2017-11-01)

Budget Impact of Intravenous Iron Therapy with Ferric Carboxymaltose in Patients with Chronic Heart Failure and Iron Deficiency in Romania
by: Lorenzovici László, et al.
Published: (2019-12-01)

A hospital based study to access the usefulness of using the combination regime of the ferric carboxy maltose, vitamin B12 and folic acid as a treatment of severe anemia among pregnant women in a rural tribal community of South Gujarat
by: Vayeda Maitri, et al.
Published: (2022-01-01)

Patient-Reported Outcomes After Ferric Carboxymaltose Treatment for Iron Deficiency Anemia: A Prospective Observational Study
by: Kwong WJ, et al.
Published: (2023-08-01)

Efficacy, Safety and Pharmacoeconomic Analysis of Intravenous Ferric Carboxymaltose in Anemic Hemodialysis Patients Unresponsive to Ferric Gluconate Treatment: A Multicenter Retrospective Study
by: Alberto Rosati, et al.
Published: (2022-09-01)

Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial
by: Giuseppe Rosano, et al.
Published: (2023-08-01)

Indirect comparison between ferric carboxymaltose and oral iron replacement in heart failure with reduced ejection fraction: a network meta-analysis
by: Edoardo Sciatti, et al.
Published: (2021-03-01)

Improvement in left atrial strain following ferric carboxymaltose in heart failure: an analysis of the Myocardial‐IRON trial
by: Enrique Santas, et al.
Published: (2024-04-01)